Go to main content

GCPharma

NEWS

The latest news
Updates on GC Pharma’s
Journey of supporting
Health and happiness.

전자공고 검색 입력 폼
Search
소식 상세 테이블 표
Title GC Pharma Reports Q1 2020 Results
Date of registration 2020-04-29
Attachment File
Contents
Q1 performance confirms return to growth
 

YONGIN, South Korea, 29 April 2020 - GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited consolidated financial results for the three months ended 31 March 2020.

First-Quarter Reported Results(1)

Key Figures

Q1 2020

Growth(2)

Total revenues

KRW 307.8 billion

+8.6%

Operating profit

KRW 6.1 billion

+283.9%

K-IFRS profit after taxation

KRW -3.9 billion

-

(1) Results from continuing operations (Green Cross MS’ blood bag business has been classified as discontinued operations) 

(2) Results and percentages compare to equivalent 2019 period   


Financial Highlights
●Delivered total revenue growth of 8.6% KRW 307.8 billion (2019 Q1: 283.3 billion), and operation profit increased 238.9% to KRW 6.1 billion (2019 Q1: 1.6 billion) in the first quarter. 

●Unconsolidated revenues increased 8.1%, reflecting strong international sales

● Double-digit growth in consolidated subsidiaries, including Green Cross MS and Green Cross LabCell

● Green Cross local sales up 5.5% reflecting strong CHC segment performance

● Green Cross international sales benefited from strong vaccines growth, Flu Vx and VZ Vx sales up 711%, 1,095% respectively

● Operating profit growth driven by favourable mix and bottom line reflected anticipated headwinds


About GC Pharma
GC Pharma is a biopharmaceutical company that delivers life-saving and life-sustaining protein therapeutics and vaccines. Headquartered in South Korea, GC Pharma is the largest plasma protein product manufacturer in Asia and has been dedicated to quality healthcare solutions more than half a century. Green Cross Corporation updates its corporate brand as GC Pharma in early 2018. Green Cross Corporation remains the company's registered, legal name.

This release includes forward-looking statements, which express the current beliefs and expectations of GC Pharma’s management. Such statements speak only as of the date on which they are made and the company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
 

# # #

List view

소식 리스트 테이블 표
Number Date of registration Title Attachment File Number of clicks
245 2024-02-13 GC Biopharma Presents Updates on its LSD Treatments at the WORLDSymposium 2024 64
244 2024-01-23 European Medicines Agency (EMA) Grants Orphan Drug Designation (ODD) to GC Biopharma's Treatment for Sanfilippo Syndrome (Type A) 59
243 2023-12-17 GC Biopharma Announces US FDA Approval for ALYGLO™ (Immune Globulin Intravenous, Human-stwk) 10% Liquid for Adults with Primary Humoral Immunodeficiency (PI) 34
242 2023-12-06 GC Biopharma’s groundbreaking for the plasma fractionation plant in Indonesia 1590
241 2023-11-30 GC Biopharma establishes mRNA production facility in Hwasun, Korea 1136
240 2023-11-06 The World’s First “Recombinant Anthrax Vaccine”: GC Biopharma applies for MFDS Approval 1183
239 2023-10-05 FDA Grants Orphan Drug Designation to GC Biopharma’s Drug Candidate for Thrombotic Thrombocytopenic Purpura 1200
238 2023-08-30 GC Biopharma to organize “Donate Blood with Love”, a healthy way of giving back to the community 594
237 2023-08-25 GC Biopharma to Produce Cholera Vaccines Jointly with Eubiologics 323
236 2023-07-31 U.S. FDA Accepts Biologics License Application for GC Biopharma's GC5107B (Immune Globulin Intravenous (Human), 10% Liquid) 920
처음으로이전 10개

12345678910

다음 10개끝으로

이메일집단수집거부

GC녹십자는 이메일 수집을 거부합니다

본 웹사이트에 게시된 이메일 주소가 전자우편 수집 프로그램이나
그 밖의 기술적 장치를 이용하여 무단으로 이메일 주소를 수집하는 행위를 거부하며,
이를 위반시 정보통신망 이용촉진 및 정보보호 등에 관한 법률에 의해 형사처벌됨을
유념하시기 바랍니다

게시일: 2003년 9월 1일